FGFR1-Selective PAM for Cartilage Anabolism
A heparin-mimetic positive allosteric modulator that potentiates endogenous FGF18-FGFR1 signaling only where ligand is already present.
recovery pam pocket: allo · ▲ 0 · platform draft · 2026-05-02 12:35
🎁 Free tier: 3 design runs / 24h per IP. Each run
produces 4 candidates with full Compounding Lab Spec Sheets — no
signup needed.
Have an API key?
Target structure — FGFR1
AlphaFold v6 · drag to rotate · scroll to zoom · UniProt P11362
Desired effect
Amplifies chondrocyte proliferation and matrix synthesis in articular cartilage by stabilizing the FGF-FGFR1-heparan sulfate ternary complex. Activity is conditional on local FGF ligand, avoiding the off-tissue mitogenic risk of direct FGFR agonists.
Mechanism rationale
The peptide mimics the heparan sulfate co-receptor groove on FGFR1, lowering the EC50 for endogenous FGF18 without triggering receptor dimerization on its own. Conditional pharmacology means tissues without active FGF ligand see no signal, sharply narrowing the oncogenic and off-target liability that has sunk prior FGFR agonist programs. Co-formulation with hyaluronate confines exposure to the joint capsule.
Novelty basis
No marketed peptide acts as a heparin-mimetic FGFR1 PAM; existing osteoarthritis FGF programs (sprifermin) use the native ligand and lack conditional selectivity.
Strategic value
Buyer profile is osteoarthritis-focused mid-caps and joint-health divisions (Galapagos, Bioventus, Sanofi consumer-health musculoskeletal, Pacira). TAM is the >$10B disease-modifying osteoarthritis drug (DMOAD) gap, where no approved agent exists and intra-articular peptides have a cleaner regulatory path than systemic biologics. GTM angle is to position as the first conditional-anabolic DMOAD, leveraging the conditional-on-ligand mechanism as both a safety story for FDA and a defensible composition-of-matter and method-of-use IP fence around sulfotyrosine-bearing FGFR1 PAMs.
Design parameters
| Primary target | FGFR1 — P11362 |
|---|---|
| Secondary targets | IGF1R |
| Binding mode | pam |
| Pocket mode | allo |
| Modality hint | 12-15 aa linear peptide with three sulfotyrosines and one D-arginine, intra-articular administration formulated in a hyaluronate vehicle |